Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.
Hollander
Priscilla A
PA
Baylor University Medical Center, Endocrinology Center, 3600 Gaston Ave., Wadley Tower, Dallas, TX 75246, USA. priscilh@baylorhealth.edu
Blonde
Lawrence
L
Rowe
Richard
R
Mehta
Adi E
AE
Milburn
Joseph L
JL
Hershon
Kenneth S
KS
Chiasson
Jean-Louis
JL
Levin
Seymour R
SR
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001682:Biological Availability; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D016001:Confidence Intervals; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage*; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D001786:Blood Glucose; C473734:Exubera; D007328:Insulin; D049528:Insulin, Long-Acting